Table 1.
RECK and EMMPRIN staining in renal cell tumors related to clinicopathological parameters
|
Variable |
Cases (n / %) |
RECK expression (number of cases / %) |
P value* |
||||
|---|---|---|---|---|---|---|---|
| 0 | 1 | 2 | 3 | ||||
| Age |
≤60 years |
197 (49.9) |
161 (81.7) |
27 (13.7) |
8 (4.1) |
1 (0.5) |
0.580 |
| |
>60 years |
198 (50.1) |
164 (82.8) |
22 (11.1) |
5 (2.5) |
7 (3.5) |
|
| Sex |
male |
264 (66.8) |
212 (80.3) |
36 (13.6) |
11 (4.2) |
5 (1.9) |
0.234 |
| |
female |
131 (33.2) |
113 (86.3) |
13 (9.9) |
2 (1.5) |
3 (2.3) |
|
| pT status |
pT1-2 |
265 (67.1) |
216 (81.5) |
32 (12.1) |
10 (3.8) |
7 (2.6) |
0.250 |
| |
pT3-4 |
130 (32.9) |
109 (83.8) |
17 (13.1) |
3 (2.3) |
1 (0.8) |
|
| Fuhrman grade |
1-2 |
348 (88.1) |
285 (81.9) |
43 (12.4) |
12 (3.4) |
8 (2.3) |
0.338 |
| |
3-4 |
47 (11.9) |
40 (85.1) |
6 (12.8) |
1 (2.1) |
0 (0.0) |
|
| Nodal status** |
pN0 |
214 (89.9) |
182 (85.0) |
25 (11.7) |
5 (2.3) |
2 (0.9) |
0.878 |
| |
pN+ |
24 (10.1) |
20 (83.3) |
3 (12.5) |
1 (4.2) |
0 (0.0) |
|
| Metastases*** |
M0 |
338 (90.6) |
278 (82.2) |
41 (12.1) |
12 (3.6) |
7 (2.1) |
0.300 |
| |
M1 |
35 (9.4) |
31 (88.6) |
3 (8.6) |
1 (2.9) |
0 (0.0) |
|
| Margin status**** |
R0 |
357 (94.4) |
291 (81.5) |
46 (12.9) |
12 (3.4) |
8 (2.2) |
0.603 |
| |
R+ |
21 (5.6) |
18 (85.7) |
2 (9.5) |
1 (4.8) |
0 (0.0) |
|
| Tumor subtype |
|
|
|
|
|
|
|
| Clear cell RCC |
322 (81.5) |
291 (90.4) |
27 (8.4) |
3 (0.9) |
1 (0.3) |
<0.001 |
|
| Papillary RCC |
|
43 (10.9) |
23 (53.5) |
11 (25.6) |
8 (18.6) |
1 (2.3) |
|
| Chromophobe RCC |
|
22 (5.6) |
10 (45.5) |
7 (31.8) |
1 (4.5) |
4 (18.2) |
|
| Oncocytoma |
|
8 (2.0) |
1 (12.5) |
4 (50.0) |
1 (12.5) |
2 (25.0) |
|
| |
|
|
EMMPRIN expression (number of cases / %) |
|
|||
| |
|
|
0 |
1 |
2 |
3 |
|
| Age |
≤60 years |
196 (49.7) |
7 (3.6) |
57 (29.1) |
70 (35.7) |
62 (31.6) |
0.479 |
| |
>60 years |
198 (50.3) |
8 (4.0) |
54 (27.3) |
87 (43.9) |
49 (24.7) |
|
| Sex |
male |
263 (66.8) |
13 (4.9) |
70 (26.6) |
102 (38.8) |
78 (29.7) |
0.797 |
| |
Female |
131 (33.2) |
2 (1.5) |
41 (31.3) |
55 (42.0) |
33 (25.2) |
|
| pT status |
pT1-2 |
265 (67.3) |
14 (5.3) |
86 (32.5) |
112 (42.3) |
53 (20.0) |
<0.001 |
| |
pT3-4 |
129 (32.7) |
1 (0.8) |
25 (19.4) |
45 (34.9) |
58 (45.0) |
|
| Fuhrman grade |
1-2 |
347 (88.1) |
15 (4.3) |
109 (31.4) |
141 (40.6) |
82 (23.6) |
<0.001 |
| |
3-4 |
47 (11.9) |
0 (0.0) |
2 (4.3) |
16 (34.0) |
29 (61.7) |
|
| Nodal status** |
pN0 |
213 (89.9) |
6 (2.8) |
63 (29.6) |
78 (36.6) |
66 (31.0) |
0.003 |
| |
pN+ |
24 (10.1) |
1 (4.2) |
1 (4.2) |
7 (29.2) |
15 (62.5) |
|
| Metastases*** |
M0 |
337 (90.6) |
15 (4.5) |
101 (30.0) |
138 (40.9) |
83 (24.6) |
<0.001 |
| |
M1 |
35 (9.4) |
0 (0.0) |
6 (17.1) |
9 (25.7) |
20 (57.1) |
|
| Margin status**** |
R0 |
356 (94.4) |
15 (4.2) |
105 (29.5) |
145 (40.7) |
91 (25.6) |
0.004 |
| |
R+ |
21 (5.6) |
0 (0.0) |
3 (14.3) |
6 (28.6) |
12 (57.1) |
|
| Tumor subtype |
|
|
|
|
|
|
|
| Clear cell RCC |
322 (81.7) |
9 (2.8) |
91 (28.3) |
128 (39.8) |
94 (29.2) |
0.813 |
|
| Papillary RCC |
42 (10.7) |
6 (14.3) |
14 (33.3) |
16 (38.1) |
6 (14.3) |
|
|
| Chromophobe RCC |
22 (5.6) |
0 (0.0) |
5 (22.7) |
9 (40.9) |
8 (36.4) |
|
|
| Oncocytoma | 8 (2.0) | 0 (0.0) | 1 (12.5) | 4 (50.0) | 3 (37.5) | ||
*Chi-square test using linear-by-linear association, significant P values <0.05 are given in bold. **157 cases were pNx or not assessed, pN+ includes all N-positive cases. ***22 cases were Mx or not assessed. ****17 cases were Rx.